Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Insulin lispro 200 U/mL vs 100 U/mL bioequivalence in type 1 diabetes
NCT03903016Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2019
- Primary completion
- Aug 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin lispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Sanofi. Primary endpoints: Maximum Insulin Concentration at 10 hours and Area Under the Insulin Concentration-Time Curve to Last Measurable Concentration at 10 hours. Started Mar 2019; status: completed.
02
Drugs
insulin lispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03903016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903016.